Bayer Aktiengesellschaft

XTRA:BAYN Stock Report

Market Cap: €18.6b

Bayer Past Earnings Performance

Past criteria checks 0/6

Bayer has been growing earnings at an average annual rate of 25.6%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 3.1% per year.

Key information

25.6%

Earnings growth rate

25.6%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate3.1%
Return on equity-2.9%
Net Margin-1.9%
Next Earnings Update05 Mar 2025

Recent past performance updates

Recent updates

Benign Growth For Bayer Aktiengesellschaft (ETR:BAYN) Underpins Stock's 25% Plummet

Nov 21
Benign Growth For Bayer Aktiengesellschaft (ETR:BAYN) Underpins Stock's 25% Plummet

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Sep 13
These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

Aug 09
Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Jun 11
These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

May 07
The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Jan 18
These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Dec 27
Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Revenue & Expenses Breakdown

How Bayer makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XTRA:BAYN Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2446,739-88014,9766,018
30 Jun 2447,113-1,26614,6965,742
31 Mar 2447,013-3,11914,4905,690
31 Dec 2347,637-2,94114,7145,835
30 Sep 2347,775-3,66714,8815,511
30 Jun 2348,7141,44815,5656,175
31 Mar 2350,4893,03716,1436,285
31 Dec 2250,7394,15016,0366,168
30 Sep 2249,8574,70015,9935,884
30 Jun 2248,3574,23915,4135,681
31 Mar 2246,3922,20214,9365,582
31 Dec 2144,0811,00014,5315,326
30 Sep 2142,95822212,4793,449
30 Jun 2141,683-7,56513,7725,010
31 Mar 2140,883-14,84913,5244,780
31 Dec 2041,400-15,56913,8864,884
30 Sep 2042,155-15,99515,1747,215
30 Jun 2043,479-7,30313,8205,100
31 Mar 2044,1382,63114,5945,267
31 Dec 1943,5452,39114,8015,282
30 Sep 1943,150-1,53015,3605,196
30 Jun 1942,58128715,2415,082
31 Mar 1939,85655714,3664,978
31 Dec 1836,7421,37413,2384,701
30 Sep 1834,9836,02713,2764,525
30 Jun 1833,7473,23712,4804,434
31 Mar 1834,4733,48612,5794,254
31 Dec 1735,0153,24912,6894,272
30 Sep 1735,2423,08712,8784,381
30 Jun 1735,4753,92412,9494,347
31 Mar 1732,7693,99112,4484,305
31 Dec 1634,9433,74312,6864,321
30 Sep 1637,4053,83712,9594,299
30 Jun 1640,1513,97113,3274,291
31 Mar 1646,1464,21014,1104,339
31 Dec 1546,0854,02514,2504,207
30 Sep 1545,5923,61614,1454,020
30 Jun 1544,5553,42913,7963,852
31 Mar 1542,7803,20613,1443,665
31 Dec 1441,3393,32612,5763,535
30 Sep 1440,4353,56911,8783,642
30 Jun 1440,1113,50111,8983,558
31 Mar 1440,2433,42512,1313,495
31 Dec 1340,1573,18912,1953,407

Quality Earnings: BAYN is currently unprofitable.

Growing Profit Margin: BAYN is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BAYN is unprofitable, but has reduced losses over the past 5 years at a rate of 25.6% per year.

Accelerating Growth: Unable to compare BAYN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BAYN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).

Return on Equity

High ROE: BAYN has a negative Return on Equity (-2.85%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bayer Aktiengesellschaft is covered by 58 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Knut WollerBaader Helvea Equity Research
null nullBanco de Sabadell. S.A.